These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20943965)

  • 1. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.
    Smith JL; Pathak VK
    J Virol; 2010 Dec; 84(24):12599-608. PubMed ID: 20943965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
    Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
    J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
    Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
    J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
    Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
    J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Insights into HIV-1 Vif-APOBEC3F Interaction.
    Nakashima M; Ode H; Kawamura T; Kitamura S; Naganawa Y; Awazu H; Tsuzuki S; Matsuoka K; Nemoto M; Hachiya A; Sugiura W; Yokomaku Y; Watanabe N; Iwatani Y
    J Virol; 2016 Jan; 90(2):1034-47. PubMed ID: 26537685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
    Pery E; Rajendran KS; Brazier AJ; Gabuzda D
    J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.
    Albin JS; LaRue RS; Weaver JA; Brown WL; Shindo K; Harjes E; Matsuo H; Harris RS
    J Biol Chem; 2010 Dec; 285(52):40785-92. PubMed ID: 20971849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
    Schröfelbauer B; Senger T; Manning G; Landau NR
    J Virol; 2006 Jun; 80(12):5984-91. PubMed ID: 16731937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
    Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
    PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
    Siu KK; Sultana A; Azimi FC; Lee JE
    Nat Commun; 2013; 4():2593. PubMed ID: 24185281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
    Dang Y; Wang X; Esselman WJ; Zheng YH
    J Virol; 2006 Nov; 80(21):10522-33. PubMed ID: 16920826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.
    Chen G; He Z; Wang T; Xu R; Yu XF
    J Virol; 2009 Sep; 83(17):8674-82. PubMed ID: 19535450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Davis RW; York IA; Zheng YH
    J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.